Joshua Boger, Alkeus Pharmaceuticals executive chairman

Bain leads $150M round to push blind­ness biotech's rare dis­ease drug to­ward FDA

Alkeus Phar­ma­ceu­ti­cals has raised $150 mil­lion via a Se­ries B round in or­der to ad­vance a pre­ci­sion med­i­cine can­di­date to treat Star­gardt dis­ease, a cur­rent­ly in­cur­able ge­net­ic dis­ease that caus­es blind­ness in chil­dren and young adults.

The news, an­nounced Mon­day, said that the fi­nanc­ing would go to­ward push­ing the drug can­di­date, gildeuretinol, to­wards the FDA and to NDA sub­mis­sion. The fi­nanc­ing will al­so be used to ex­pand the com­pa­ny — but ex­act specifics weren’t dis­closed.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.